NEW YORK (GenomeWeb) – Transgenomic today announced that it has amended its license agreement with Exiqon to include the rights to Exiqon's locked nucleic acid (LNA) oligonucleotides.

The new agreement provides Transgenomic with access to LNA oligos for use with all of its mutation enrichment technologies, including multiplexed ICE COLD-PCR. It also covers worldwide commercial use of LNA oligos for analysis of all cancer genes on all platforms, including next-generation sequencing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.